

## PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 86619

Title: Efficacy and safety of semaglutide in non-alcoholic fatty liver disease

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05911905
Position: Peer Reviewer
Academic degree: MD

**Professional title:** Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Canada

Manuscript submission date: 2023-06-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-06-28 13:12

Reviewer performed review: 2023-07-10 21:13

**Review time:** 12 Days and 8 Hours

	[Y] Grade A: Excellent [] Grade B: Very good [] Grade C:
Scientific quality	Good
	[ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	[ ] Grade A: Excellent [ Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No creativity or innovation
mis manuscript	[ ] Grade D. Ivo creativity of filliovation



https://www.wjgnet.com

Scientific significance of the	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair
conclusion in this manuscript	[ ] Grade D: No scientific significance
Language quality	[ Y] Grade A: Priority publishing [ ] Grade B: Minor language
	polishing [ ] Grade C: A great deal of language polishing [ ]
	Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority)
	[ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ]Yes [Y]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [ Y] No

### SPECIFIC COMMENTS TO AUTHORS

Dr. Zhu and his colleague systemically reviewed the effect of Semaglutide on non-alcoholic fatty liver disease in this meta analysis. Unlike pervious report, their work only focused on the biopsy or imaging scan -confirmed NAFLD RCT studies, with histological outcomes reported. General speaking, it is a well-designed and well-written meta-analysis. However, some minor revisions are needed: Table 1: Newsome (2020) should be Newsome (2021) Loomba(2023) for be study Male/ female: 22(31)/49/(71. should 22(31)/49(69) Age (SD): 59 (9.0) should be 59.5(8.0) For result section, please as mention related Figures in the text. For example: Semaglutide was associated with a significantly higher likelihood of NASH resolution with no worsening of liver fibrosis (OR 3.18, 95% CI 1.70 to 5.95, I2 = 0% Fig2A)., which will make the manuscript more readable.



## PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 86619

Title: Efficacy and safety of semaglutide in non-alcoholic fatty liver disease

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05560872 Position: Peer Reviewer Academic degree: MD

**Professional title:** Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Canada

Manuscript submission date: 2023-06-28

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-07-29 11:25

Reviewer performed review: 2023-08-06 10:22

**Review time:** 7 Days and 22 Hours

[Y] Grade A: Excellent [] Grade B: Very good [] Grade C:
Good
[ ] Grade D: Fair [ ] Grade E: Do not publish
[ Y] Grade A: Excellent [ ] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty
[Y] Grade A: Excellent [] Grade B: Good [] Grade C: Fair [] Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	[Y] Grade A: Excellent [] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
	[V] Cuada A. Drianitry muhlishina [] Cuada P. Minau languaga
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language
	polishing [ ] Grade C: A great deal of language polishing [ ]
	Grade D: Rejection
Conclusion	[Y] Accept (High priority) [] Accept (General priority)
	[ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y]Yes [ ]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [ Y] No

# SPECIFIC COMMENTS TO AUTHORS

Comment:Should the 'wong outcome (n=1)' in the Figure 1 be 'wrong outcome (n=1)'?



## PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 86619

Title: Efficacy and safety of semaglutide in non-alcoholic fatty liver disease

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04025443

Position: Editorial Board

Academic degree: MD, PhD

**Professional title:** Doctor, Senior Researcher

Reviewer's Country/Territory: Russia

Author's Country/Territory: Canada

Manuscript submission date: 2023-06-28

**Reviewer chosen by:** Geng-Long Liu

Reviewer accepted review: 2023-07-28 07:09

Reviewer performed review: 2023-08-07 21:12

**Review time:** 10 Days and 14 Hours

Scientific quality	[Y] Grade A: Excellent [] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[ Y] Grade A: Excellent [ ] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	[Y] Grade A: Excellent [] Grade B: Good [] Grade C: Fair [] Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	[ Y] Grade A: Excellent [ ] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[ ] Grade A: Priority publishing [ Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ]Yes [Y]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous  Conflicts-of-Interest: [ ] Yes [Y] No

### SPECIFIC COMMENTS TO AUTHORS

Dear colleagues! I read with pleasure and interest your manuscript entitled "Efficacy and safety of semaglutide in non-alcoholic fatty liver disease: A systematic review and meta-analysis". In this properly registered and adequately performed study based on the analysis of the data obtained in 3 available clinical trials you showed that semaglutide has beneficial histological, radiologic, liver enzyme, and cardiometabolic effects in patients with NAFLD, with a well-tolerated safety profile. These results evidently fill knowledge gap and may be interesting to the readers. I did not detect any major flaws and suppose that the paper may be published as is.